X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Outlook Therapeutics intends to use the net proceeds to fund its ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an investigational ophthalmic formulation under development as an intravitreal injection for wet AMD and other retinal diseases.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Syntone Ventures
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 15, 2024
Details:
ONS-5010 (bevacizumab) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
Outlook Therapeutics intends to use the net proceeds to fund its ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an investigational ophthalmic formulation under development as an intravitreal injection for wet AMD and other retinal diseases.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $159.0 million Upfront Cash: $60.0 million
Deal Type: Private Placement March 18, 2024
Details:
ONS-5010 (bevacizumab-vikg) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated in phase 3 cliical trials for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Outlook Therapeutics intends to use the proceeds to fund its ONS-5010/Lytenava, an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD, including to initiate and fund the planned NORSE EIGHT trial.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Great Point Partners
Deal Size: $172.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 23, 2024
Details:
ONS-5010 (bevacizumab-biosimilar) is a VEGF-A inhibitor antibody which is being evaluated in phase 3 clinical trials for the treatment of neovascular age-related macular degeneration & wet macular degeneration,
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
ONS-5010 (bevacizumab-vikg) is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human VEGF. It is being evaluated in phase 3 cliical trials for the treatment of wet age-related macular degeneration.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
ONS-5010 ((bevacizumab-vikg) is an investigational ophthalmic formulation which is act as vascular endothelial growth factor inhibitor and investigated for the treatment of wet AMD.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lytenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
ONS-5010 ((bevacizumab-vikg) is an investigational ophthalmic formulation which is act as vascular endothelial growth factor inhibitor and investigated for the treatment of wet AMD.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: ONS-5010
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
Lyntenava (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other approved retinal diseases.
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: Lyntenava
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brookline Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
